Pulmonary Fibrosis is a chronic and progressive lung disease characterized by the scarring and thickening of lung tissues. It affects the ability of the lungs to function properly, leading to breathing difficulties and reduced oxygen supply to the body.
The prevalence of Pulmonary Fibrosis varies across different populations and regions. According to available data, it is estimated that around 200,000 people in the United States are living with this condition. However, it is important to note that this number may be an underestimation as many cases go undiagnosed or misdiagnosed.
Pulmonary Fibrosis can affect individuals of all ages, but it is more commonly diagnosed in adults over the age of 50. It is slightly more prevalent in men than women. Certain risk factors such as smoking, exposure to environmental pollutants, certain medications, and genetic predisposition can increase the likelihood of developing the disease.
While Pulmonary Fibrosis is considered a rare disease, its prevalence is increasing. This may be due to improved awareness, better diagnostic techniques, and an aging population. Early detection and proper management are crucial in improving the quality of life for individuals living with Pulmonary Fibrosis.